Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
79,446 results
  • Inferring the long duration response to levodopa in Parkinson's disease. [Journal Article]
  • PRParkinsonism Relat Disord 2018 Sep 06
  • Nagao K, Ding C, … Kempster PA
  • CONCLUSIONS: Long duration responses contribute almost half of the total levodopa benefit during the first decade of treatment. An appreciation of both long and short duration components of drug symptomatic effects is important in clinical trial design to investigate possible neuroprotective treatments.
  • An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates. [Journal Article]
  • MDMov Disord 2018 Sep 14
  • Charvin D, Di Paolo T, … Conquet F
  • CONCLUSIONS: This work provides a demonstration that a positive allosteric modulator of metabotropic glutamate receptor 4 can alleviate the motor symptoms of PD and the motor complications induced by l-dopa in primates. PXT002331 is the first compound of its class to enter phase IIa clinical trials. © 2018 International Parkinson and Movement Disorder Society.
New Search Next